OBJECTIVES: There has been disruption to the detection and management of those with hypertension and atrial fibrillation (AF) during the COVID-19 pandemic. This is likely to vary geographically and could have implications for future mortality and morbidity. We aimed to estimate the change in diagnosed prevalence, treatment and prescription indicators for AF and hypertension and assess corresponding geographical inequalities.

METHODS: Using the Quality and Outcomes Framework (2016/17 to 2021/22) and the English Prescribing Datasets (2018 to 2022), we described age-standardized prevalence, treatment and prescription item rates for hypertension and AF by geography and over time. Using an interrupted time-series (ITS) analysis we estimated the impact of the pandemic (from April 2020) on missed diagnoses and on the percentage change in medicines prescribed for these conditions. Finally, we described changes in treatment indicators against Public Health England 2029 cardiovascular risk targets.

RESULTS: We observed 143,822 fewer (-143,822,95%CI:-348,292, 60,655) diagnoses of hypertension, 60,330 fewer (-60,330,95%CI:-125,934, 5,311) diagnoses of AF and 1·87% fewer (-1·87,95%CI:-4·92%, 1·40%) prescriptions for these conditions over the COVID-19 impact period. There was variation across geography in England in terms of the indirect impact of the COVID-19 pandemic on the diagnosis, prescription, and treatment rates of hypertension and AF. 20% of Sub Integrated Care Boards account for approximately 62% of all missed diagnoses of hypertension. The proportion of individuals who had their hypertension controlled fell from 75·8% in 2019/20 to 64·1% in 2021/22 and the proportion of individuals with AF who were risk assessed fell from 97·2% to 90·7%.

CONCLUSIONS: Hypertension and AF detection and management was disrupted during the COVID-19 pandemic however the disruption varied considerably across diseases and geography. This highlights the utility of administrative and geographically granular datasets to inform targeted efforts to mitigate the indirect impacts of the pandemic through applied secondary prevention measures.